Altaris to Acquire Sharecare in an All-Cash Deal for $444.3 Million

Digital health company Sharecare Inc. (SHCR) on June 21, 2024, agreed to be acquired by an affiliate of Altaris, LLC for $444.3 million in cash.

Deal Structure:

Under the terms of the agreement, Altaris will acquire Sharecare for $1.43 per share in cash; representing a premium of 84.75% over the closing price of Sharecare on June 20, 2024.

Company Profile:

Sharecare is a leading digital health company that unifies and manages health through a comprehensive, data-driven platform, optimizing well-being and making high-quality care accessible and affordable. Sharecare went public through a merger with a blank-check firm backed by veteran investment banker Alan Mnuchin.

Altaris, headquartered in New York City, is an investment firm focused on building market-leading, innovative, and efficient healthcare companies to improve patient access and outcomes. It manages about $10 billion in equity capital.

Deal Details and Timeline:

Upon the completion of the acquisition, which is expected in the second half of 2024, Sharecare will no longer be listed on Nasdaq.

Sharecare’s current Price/Sales (TTM) ratio is 0.65, below the sector median of 3.45.

Jeff Arnold, Sharecare’s founder and executive chairman of the Board of Directors, and the Chief Executive Officer, Brent Layton, will continue in their respective roles following the closing.

Deal Metrics:

For more detailed information about this merger and acquisition transaction, please visit the Deal Metrics page here:

Deal Metrics for the acquisition of Sharecare Inc. (SHCR) by Altaris, LLC.

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart from the merger announcement through its eventual completion or failure.
• A timeline of every event as the merger progresses, including the expiration of the HSR period, regulatory approvals, shareholder votes, etc.
• News and SEC filings.
• A history of deal updates.
• And much more.

Disclaimer: Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article